Microcrystalline Cellulose MCC Market

Growing Pharmaceutical industry to boost the market growth

Microcrystalline cellulose is used in the pharmaceutical industry as a stabilizer, binder, film-forming agent, suspension agent, and disintegrate in tablet formulations, ointments, and other topical therapeutic bases. MCC is one of the most important and widely used excipients in the pharmaceutical industry. It is a key diluent and is used as a binding agent in pharmaceutical formulations. It is extensively used in drug preparations such as tablets, capsules, sachets, and so on. The growing production of pharmaceutical products is further driving the market.

Emerging countries such as China, Brazil, and India are the rapidly-growing the demand for microcrystalline cellulose market revenue.

Further, growth in consumption of processed foods across the globe majorly drives the market. Increase in consumption of processed food has augmented the use of MCC as an additive, which in turn boosts the market growth. Moreover, consumption of pharmaceutical products, such as tablets and capsules, is expected to fuel the demand for MCC. However, volatile prices and availability of substitute products have restricted the market growth. Conversely, rise in disposable income of population in developing economies in Asia-Pacific is anticipated to provide new opportunities for the key players.

Additionally, increasing application of microcrystalline cellulose in various industries is a major factor propelling growth of the microcrystalline cellulose market. For instance, microcrystalline cellulose is used as stabilizer, gelling agent, suspending agent, and anti-caking agent in beverages. It is also used as a cold and hot stabilizer, in frozen food, ice cream, and canned meat, in order to improve the shelf life of these products.

However, microcrystalline cellulose is widely used in pharmaceuticals, owing to its tastelessness, odorlessness, and chemical inertness properties. According to the International Trade Administration, in 2021, the market for pharmaceuticals is projected to grow from around US$ 1.22 trillion in 2021 to US$ 1.42 trillion by 2021. Steadily growing pharmaceutical industry is expected to support market growth of microcrystalline cellulose over the forecast period. Therefore, growing demand for pharmaceutical industry has enhanced the microcrystalline cellulose market CAGR across the globe in the recent years.

The Global Microcrystalline Cellulose Market Industry experiences a notable surge in demand from the food sector, where it serves as a stabilizer, thickener, and anti-caking agent. As consumers increasingly seek clean-label products, manufacturers are incorporating microcrystalline cellulose to enhance texture and improve shelf life. In 2024, the market is projected to reach 1.36 USD Billion, driven by the growing trend of health-conscious eating. This demand is expected to continue, as the food industry increasingly recognizes the benefits of microcrystalline cellulose, suggesting a robust growth trajectory for the industry.

By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. Asia-Pacific microcrystalline cellulose market accounted for USD 0.47 billion in 2021 and is expected to exhibit a significant CAGR growth during the study period. This is attributed to steadily growing food and pharmaceutical industries as microcrystalline cellulose has high demand in pharmaceuticals and is extensively used as functional ingredient in food and beverages across the region. Moreover, China microcrystalline cellulose market held the largest market share, and the India microcrystalline cellulose market was the fastest growing market in the Asia-Pacific region.

Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: MICROCRYSTALLINE CELLULOSE MARKET SHARE BY REGION 2021 (%)Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe microcrystalline cellulose market accounts for the second-largest market share due to the increasing government-backed investments in drug development and improvements in the quality of pharmaceutical products are anticipated to bode well for the market in this region. Further, the Germany microcrystalline cellulose market held the largest market share, and the UK microcrystalline cellulose market was the fastest growing market in the European region.

The Asia-Pacific microcrystalline cellulose Market is expected to grow at the fastest CAGR from 2022 to 2030. This is due to the economic recovery and the increase in employment rate are the growth factors in the region, which, in turn, supports the growth of the market Moreover, China microcrystalline cellulose market held the largest market share, and the India microcrystalline cellulose market was the fastest growing market in the Asia-Pacific region.

Major market players are spending a lot of money on R&D to increase their product lines, which will help the microcrystalline cellulose market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the microcrystalline cellulose industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the microcrystalline cellulose industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, microcrystalline cellulose industry has provided medicine with some of the most significant benefits. The microcrystalline cellulose market major player such as DuPont, Asahi Kasei Corporation, JRS Pharma, Roquette Frères, and others are working to expand the market demand by investing in research and development activities.

Asahi Kasei Medical Co., Ltd. manufactures and distributes medical devices. The Company produces dialyzers, therapeutic apheresis products, leukocyte reduction filters, virus removal filters, and other products. Asahi Kasei Medical markets its products throughout Japan. In June 2022, Asahi Kasei Medical has completed its acquisition of Bionova Scientific, LLC, a provider of contract process development services and GMP-compliant contract manufacturing services to biopharmaceutical companies. Bionova Scientific will operate as a business unit within Asahi Kasei Medical’s bioprocess division.

Bionova Scientific will continue to expand its business by building on its strengths as a CDMO specialized in the process design and manufacture of various types of biologics such as microcrystalline cellulose, cytokines, vaccines, hormones etc.

Also, DFE Pharma is a leader in pharma- and nutraceutical excipient solutions. The company develop, produce and supply high-quality functional excipients for use in the pharmaceutical, biopharmaceutical, and nutraceutical industries for respiratory, oral solid dose (OSD), ophthalmic and parenteral formulations. In July 2021, DFE Pharma, a provider of pharmaceutical Excipient solutions, launched Pharmacel sMCC 90, a silicified variant of microcrystalline cellulose. The new product is developed as a synergistic solution for challenging oral solid dosage formulations. It offers increases surface area, enhanced powder flow, and superior tablatibility, thereby improving formulation robustness.